Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098264 | PMC |
| http://dx.doi.org/10.1038/bcj.2016.92 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nanoparticle innovations in targeted cancer therapy: advancements in antibody-drug conjugates.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, 11829, Cairo, Egypt.
Antibody-drug conjugates (ADCs) have emerged as a promising strategy in targeted cancer therapy, enabling the precise delivery of cytotoxic agents to tumor sites while minimizing systemic toxicity. However, traditional ADCs face significant limitations, including restricted drug loading capacity, where an optimal drug-to-antibody ratio (DAR) is crucial; low DARs may lead to insufficient potency, while high DARs can cause rapid clearance and increased toxicity. Additionally, ADCs often suffer from instability in circulation due to the potential for premature release of cytotoxic agents, resulting in off-target effects and reduced therapeutic efficacy.
View Article and Find Full Text PDFBio-fabrication of chitosan-stabilized magnesium oxide nanomaterials: Investigation of photocatalytic, in vitro cytotoxicity activities and apoptosis in oral squamous carcinoma cells.
Int J Biol Macromol
January 2025
Centre of Advanced Study in Marine Biology, Annamalai University, Parangipettai 608 502, Tamil Nadu, India.
A bio-fabrication approach is a novel way to develop chitosan-stabilized magnesium oxide nanomaterials (cMgO-NMs). The process involves utilizing polymeric chitosan as the reducing and stabilizing agent. The characteristics of the developed cMgO-NMs were determined using various spectroscopical techniques.
View Article and Find Full Text PDFEffective Reduction of Transgene-Specific Immune Response With rAAV Vectors Co-Expressing miRNA-UL112-5p or ERAP1 shRNA.
J Cell Mol Med
January 2025
Institute of Molecular Medicine, Huaqiao University, Quanzhou, China.
Recombinant adeno-associated virus (rAAV) has emerged as one of the best gene delivery vectors for human gene therapy in vivo. However, the clinical efficacy of rAAV gene therapy is often hindered by the host immune response against its transgene products. Endoplasmic reticulum aminopeptidase 1 (ERAP1) is specialised to process peptides presented by class I molecules of major histocompatibility complex.
View Article and Find Full Text PDFTargeting CD45 by gene-edited CAR T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioning.
Mol Ther Oncol
September 2024
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Hematopoietic stem cell transplantation (HSCT) is widely used to treat patients with life-threatening hematologic and immune system disorders. Current nontargeted chemo-/radiotherapy conditioning regimens cause tissue injury and induce an array of immediate and delayed adverse effects, limiting the application of this life-saving treatment. The growing demand to replace canonical conditioning regimens has led to the development of alternative approaches, such as antibody-drug conjugates, naked antibodies, and CAR T cells.
View Article and Find Full Text PDFGender and sex differences in colorectal cancer screening, diagnosis and treatment.
Clin Transl Oncol
January 2025
Department of Medical Oncology, University Hospital of Navarra, Instituto de Investigación Sanitaria de Navarra, IdISNA, Navarra, Spain.
Males have a higher incidence and mortality rate from colorectal cancer (CRC) compared with females. This review examines the reasons for these differences, including risk factors, screening participation, interpretation of screening tests, presentation and tumour types, pathophysiology (particularly the impact of sex hormones on tumour-related gene expression, microsatellite instability, micro-RNA expression, and the tumour microenvironment), and the efficacy and toxicity of treatment. Sex differences in hormones and body composition are responsible for some of the sexual dimorphism in CRC incidence and outcomes, particularly the pathophysiology, CRC presentation, the pharmacokinetics of cytotoxic therapies, and the impact of treatment on outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!